Vertex reported positive Phase 2b measures tied to a urine-based endpoint for its kidney disease candidate inaxaplin, while looking ahead to pivotal readouts. The company said improvements were observed in two separate patient populations, supporting momentum for an expanded kidney label beyond an initial target group. The update comes as Vertex aims to broaden positioning in chronic kidney disease and diabetes-adjacent renal markets, where competitive differentiation depends on biomarker-linked outcomes and clear clinical trajectories. Next year’s pivotal readout will determine how durable the signal is and whether the program can translate urine biomarker effects into clinically meaningful endpoints for regulatory review.